Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Intelgenx Technologies Corp (OP: IGXT ) N/A UNCHANGED Last Price Updated: 3:57 PM EDT, May 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Intelgenx Technologies Corp < Previous 1 2 3 4 Next > IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q1 2024 May 15, 2024 Intelgenx Technologies just reported results for the first quarter of 2024. Via InvestorPlace IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023 March 21, 2024 Intelgenx Technologies just reported results for the fourth quarter of 2023. Via InvestorPlace Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More January 15, 2024 Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024. Via Benzinga IntelGenx Q2 2023: Revenue Decline 67%, Operating Costs Rise, What About Net Loss? August 14, 2023 IntelGenx Technologies Corp. (TSX: IGX) (OTC: IGXT), a drug delivery company focused on the development and manufacturing of pharmaceutical films, reported its financial results on Monday for the... Via Benzinga Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More May 15, 2023 Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... Via Benzinga FDA Gives Nod To IntelGenx's Migraine Solution As Revenues Plunge 32%; Q1 Results Report May 11, 2023 IntelGenx Technologies Corp. (OTC: IGXT) reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, amounting to $162,000 as compared to $237,000 in the same Via Benzinga Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More April 05, 2023 Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin... Via Benzinga IntelGenx's Q4 And Full-Year 2022 Financials, 'On The Cusp' Of Rapid Growth? March 30, 2023 Drug delivery company IntelGenx Technologies Corp. (OTCQB: IGXT)’s financial results for the three and twelve months ended December 31, 2022 show: Via Benzinga GH Research, Mind Medicine Among Top Psychedelic Movers Of Today January 31, 2023 Via Benzinga Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today January 30, 2023 Via Benzinga Cybin, GH Research Among Top Psychedelic Movers Of Today January 27, 2023 Via Benzinga Psychedelic Stock Gainers And Losers From January 26, 2023 January 26, 2023 Via Benzinga Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today January 25, 2023 Via Benzinga Psychedelic Stock Gainers And Losers From January 24, 2023 January 24, 2023 Via Benzinga Psychedelic Stock Gainers And Losers From January 19, 2023 January 19, 2023 Via Benzinga GH Research, Cybin Among Top Psychedelic Movers Of Today January 16, 2023 Via Benzinga Psychedelic Stock Gainers And Losers From January 13, 2023 January 13, 2023 Via Benzinga Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today January 12, 2023 Via Benzinga Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results January 12, 2023 After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche Via Benzinga IntelGenx Reports Q3 2022 Financial Results, Management Anticipates Psychedelics Trials In 2023 November 10, 2022 IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) reported its financial results late Thursday for the third quarter that ended September 30, 2022. Via Benzinga New Oral Film Tech Improving Cannabinoid Onset Seeks Patent Protection November 03, 2022 Pharmaceutical films leader IntelGenx Corp. (OTCQB: IGXT) filed a provisional patent application with the U.S. Via Benzinga Canadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA Track October 25, 2022 Drug delivery company IntelGenx Corp. Via Benzinga Short Volatility Alert: IntelGenx Technologies Corp. October 04, 2022 On Monday, shares of IntelGenx Technologies Corp. (OTC: IGXT) experienced volatile short activity. After the activity, the stock price went up +7.69% to $0.13. The overall sentiment for IGXT has been... Via Benzinga ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today August 01, 2022 GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 4.95% at $0.34 Via Benzinga Psychedelic Stock Gainers And Losers From July 29, 2022 July 29, 2022 GAINERS: Numinus Wellness (OTC:NUMIF) shares closed up 11.30% at $0.22 Via Benzinga Small Pharma, Cybin Among Top Psychedelic Movers Of Today June 09, 2022 GAINERS: Small Pharma (OTC:DMTTF) shares closed up 12.55% at $0.13 Via Benzinga Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today June 08, 2022 GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78 Via Benzinga Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today June 07, 2022 GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72 Via Benzinga ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today June 06, 2022 GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36 Via Benzinga Psychedelic Stock Gainers And Losers From June 3, 2022 June 03, 2022 GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.88% at $0.35 Via Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
